1. Home
  2. BW vs AGIO Comparison

BW vs AGIO Comparison

Compare BW & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$7.92

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$33.62

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BW
AGIO
Founded
1867
2007
Country
United States
United States
Employees
1650
N/A
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
2.0B
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
BW
AGIO
Price
$7.92
$33.62
Analyst Decision
Buy
Buy
Analyst Count
2
8
Target Price
$8.00
$38.88
AVG Volume (30 Days)
4.9M
777.0K
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
41.46
N/A
EPS
N/A
N/A
Revenue
$1,062,388,000.00
$43,011,000.00
Revenue This Year
$41.58
$76.75
Revenue Next Year
$66.70
$170.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.64
$22.24
52 Week High
$22.03
$46.00

Technical Indicators

Market Signals
Indicator
BW
AGIO
Relative Strength Index (RSI) 38.39 48.19
Support Level $6.75 $32.54
Resistance Level $11.34 $36.04
Average True Range (ATR) 0.47 1.28
MACD 0.08 0.10
Stochastic Oscillator 23.51 42.77

Price Performance

Historical Comparison
BW
AGIO

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: